2022 Hybrid annual Meeting Program

POSTERS Poster Displays PD41 Role of Artificial Intelligence in Improving Access to COVID-19 Expo Hall and Virtual Diagnosis During Pandemic Meeting Platform PD42 Diagnosis of Chronic Diseases COVID & Patient/Public/ During the COVID-19 Pandemic Children Through Telemedicine PD33 Development and Validation of PD43 Estimating Societal Costs a Machine Learning-Based Prediction Associated with Vision Loss and Delayed Model for COVID-19 Diagnosis Using Cataract Surgery: The Potential Impact Patients’ Metabolomic Profile Data of the COVID-19 Pandemic PD34 Neuron-specific Biomarkers PD44 Realistic Review: Theoretical Associated with Neurological Model for Monitoring and Evaluation Manifestations in COVID-19: An (M&E) of HTA Management Evidence Mapping Systematic Review PD45 Paying for Digital Health: What PD35 Mortality and Risk Factors Evidence is Needed? Associated with Dialysis Patients with COVID-19 in a Brazilian Supplementary PD46 Multi-criteria Decision Analysis Health Service in Healthcare: Scientometric and Bibliometric Analysis PD36 Outcomes of Centenaries Hospitalized due to COVID-19 in a PD48 Does Unmet Need Influence the Private Healthcare System Scottish Medicines Consortium Health Technology Assessment Decisions for PD37 High-Dose Vitamin D for the Rare Disease Conditions? Treatment of Covid-19 PD49 Burden and Cost Oo Anterior PD38 Telehealth Use to Fight the Cruciate Ligament Reconstruction Aad Covid-19 Pandemic in a Brazilian Private Reimbursement of its Treatment in Healthcare System Indonesia: An Observational Study PD39 Strategies to Assist People with PD50 Value of Healthcare Journey for Disabilities During Health Emergencies, Patients with Rare Diseases in Brazilian Concerning the COVID-19 – Systematic Public Healthcare System: Methods and Review Preliminary Results PD40 Antigen Diagnostic Tests with Self- PD51 Patient Perspective: A Preliminary Collection of Biological Material for the Analysis of the First Year of the Patient Diagnosis of COVID-19 Involvement in Conitec´s Meetings 101

POSTERS PD52 The Role of Public Consultations PD19 Machine Learning Modelling for in Conitec’s Recommendations Between Clinical Trial Design Using the NIHR 2012 And 2020: An Introductory Innovation Observatory’s ScanMedicine Analysis Database PD53 Improving Patient Involvement PD64 Developing a Re-assessment in the National Institute for Health and Process for Non-medicine Health Care Excellence’s Appeals Process Technologies in Wales PD54 Burden of Disease and Risk Late Lifecyle RWD Factors Among Children Under 5 years & Quality of Care & in China from 1990 to 2019 Disinvestment PD55 Evidence-Based Practices to PD20 Real-World Evidence to Support Well-Being and School Success Support Single Arm Trials of Oncology of Children and Youth in Out-of-Home Interventions: Necessity or ‘NICE’ to Care Have? PD56 Conceptual Issues in the Valuation PD21 Data Sources and Real-World of Health States in Children Data on Medical Devices in the Brazilian Scenario Early & General Lifecycle PD22 Exploratory Analysis of a Brazilian PD14 A New Equitable Biomedical Real-World Open Database Applied to Research and Development Model: Prostate Cancer Preliminary Findings From a Pilot Study Applying VALIDATE Value Methods PD23 Assessing the Suitability of Real- World Data for Answering Decision PD15 Horizon Scanning to Nominate Problems – NICE’s Data Suitability Subsidy Evaluation Topics for Medical Assessment Tool Technologies: Early Experience from Singapore PD24 Robust Real-World Evidence Generation in Comparative Effectiveness PD16 Reassessment and Selection Studies – NICE’s Methods Framework Strategy of Dipeptidyl Peptidase-4 Inhibitors for Ministry Of Health Malaysia PD25 Use of Real-World Evidence in the Medicine Formulary Reimbursement Assessment of Medical Devices PD17 Automating the Impact Reporting of NICE Guidance PD68 Disinvestment Initiatives in Healthcare: A Scoping Review of PD18 Early Value Assessments of Systematic Reviews Technologies in the NICE Diagnostics Assessment Programme 102

POSTERS Lifecycle (Cost) PD11 Cost-Effectiveness of Continuous Effectiveness Glucose Monitoring for Paediatric Patients with Type 1 Diabetes Compared PD01 Using ELISA Tests for Monitoring with Self-Monitoring of Blood Glucose Response to Anti-TNFs in Rheumatoid Arthritis: Findings From a NICE Health PD12 Quality Assessment of Health Technology Assessment Economic Evaluation on Screening Programs from China PD02 A Literature Review of Treatment Schemes and Effects of Beta- PD13 Methodologies In Economic thalassemia in China Evaluations Of Biomarkers – A Systematic Review PD03 Sedimentation of Health Technology Assessment In Hospitals: A PD65 Efficacy and Safety of High Scoping Review Intensity Focused Ultrasound in Parkinson’s Disease PD04 Supporting the Social Integration of Persons with Brain Injury Using PD66 An External Combined Occipital Psychoactive Substances: A Health and Trigeminal Neurostimulation Device Technology and Intervention for Migraine Treatment Assessment PD67 The Importance of Flexible PPI PD05 Novel Non-Thermal Ablation Approaches: Case Study on Flash Technology for the Treatment of Atrial Glucose Monitoring Fibrillation PD66 An External Combined Occipital PD07 Cost-effectiveness pf Non-vitamin and Trigeminal Neurostimulation Device K Antagonist Oral Anticoagulants in for Migraine Treatment Chinese Patients With Atrial Fibrillation Oncology PD08 A Systematic Review of Reporting Quality of Economic Evaluations in TCM PD26 Overscreening for Older Women in NRDL of China Based on CHEERS in Cervical and Breast Cancer Screening in Japan PD09 Comparing Long-Term Costs Associated with Intraocular PD27 Health-Related Quality of Life Lens Selection and Nd:YAG Laser and Utility Scores of Lung Cancer Capsulotomy in the UK: A Cost- Patients Treated with Traditional Chinese Consequence Analysis Medicine in China PD10 Quality of Economic Evaluation PD28 Cost-Effectiveness of Selective of Coronary Stents Based on CHEERS: A Internal Radiation Therapy Using Y-90 Scoping Review Resin Microspheres for Unresectable Hepatocellular Carcinoma in Brazil 103

POSTERS PD29 Systematic Review with Meta- PD58 Implementation and Assessment analysis of Pharmacokinetic Parameters of a Lung Cancer Screening Pilot Project of Tyrosine Kinase Inhibitors Used in in Québec Through Multi-Stakeholder Chronic Myeloid Leukemia Collaboration PD30 The Radioactive Seed Localization PD59 Collaborative Strategies Between and Radio-Guided Occult Lesion Regulatory and Health Technology Localization for Non-Palpable Breast Assessment Bodies: Results of Teaching Cancer Surgery: A Meta-Analysis and Learning Initiatives PD31 A Pragmatic and Expedited PD60 What are the Opportunities and Evaluation of Companion Diagnostics Challenges to Implement Value Based for Guiding Cancer Drug Use Healthcare (VHBC) Pilots in Brazilian Private Healthcare System? PD32 Cost-Utility of Selective Internal Radiation Therapy Using Y-90 Resin Pricing & MEA Microspheres for Chemotherapy- Refractory Metastatic Colorectal Cancer PD61 What are the Drivers to in Brazil Transitioning from FFS to Value-Based Payments Models in the Brazilian Private Patients & Capacity Healthcare System? Building PD62 Supporting Appropriate Medicines PD57 Managing Innovation: A Qualitative Use Through the Lifecycle: Bringing Analysis of Different Structures in Health Standardised Patient Data Into Clinical and Social Services Institutions Practice with the H2O Project 104

HTAi and Associated Meetings

HTAI AND ASSOCIATED MEETINGS HTAi and HTAi Policy Forum Associated Meetings and Meetings Sessions Saturday, June 25, 2022 Sunday, June 26, 2022 HTAi Board of Directors Meeting Global Policy Forum: The Business and (Invitation Only) Topic Scoping Meeting (Invitation Only) 08:30 – 16:30, Room 116 (1st Floor) 09:00 – 12:00, Room 417 (4th Floor) Sunday, June 26, 2022 Monday, June 27, 2022 Euroscan Meeting (Invitation Only) 13:00 – 15:30, Room 417 (4th Floor) HTA 2025 and Beyond: Lifecycle Approaches to Promote Engagement HTAi Scientific Development and and Efficiency in Health Technology Capacity Building (SDCB) Committee Assessment (2022 Global Policy Forum) Meeting (Invitation Only) 16:30 – 17:30, Room 417 (4th Floor) 14:20 – 15:35, Beatrix Theatre (Ground Floor) Monday, June 27, 2022 Deliberative Processes for Informed Annual General Meeting (AGM) Decision Making by Health Technology Assessment 19:00 – 20:00, Beatrix Theatre (Ground (2021 Latin America Policy Forum) Floor) 17:15 – 18:30, Beatrix Theatre (Ground Tuesday, June 28, 2022 Floor) IJTAHC Editorial Board Meeting Tuesday, June 28, 2022 (Invitation Only) 12:55 – 13:55, Room 110 (1st Floor) HTA in Asia Post-COVID-19 (2021 Asia Policy Forum) 16:55 – 18:10, Beatrix Theatre (Ground Floor) 106

HTAI AND ASSOCIATED MEETINGS HTAi Interest Group Meetings Monday, June 27, 2022 Tuesday, June 28, 2022 HTAi Interest Group Meeting: Hospital HTAi Interest Group Meeting: Ethics in Based HTA HTA 12:30 – 13:30, Room 417 (4th Floor) 12:55 – 13:55, Room 315 (3rd Floor) HTAi Interest Group Meeting: Real HTAi Interest Group Meeting: Patient World Evidence & Artificial Intelligence and Citizen Involvement 12:30 – 13:30, Room 215 (2nd Floor) 12:55 – 13:55, Room 215 (2nd Floor) HTAi Interest Group Meeting: Medical HTAi Interest Group Meeting: Public Devices Health 12:30 – 13:30, Room 315 (3rd Floor) 12:55 – 13:55, Room 417 (4th Floor) HTAi Interest Group Meeting: Disinvestment & Early Awareness 18:15 – 19:15, Room 417 (4th Floor) HTAi Interest Group Meeting: HTA in Developing Countries 18:15 – 19:15, Room 215 (2nd Floor) HTAi Interest Group Meeting: Information Retrieval 18:15 – 19:15, Room 315 (3rd Floor) 107

Novartis sponsored symposium at the Health Technology Assessment international 2022 Annual Meeting Facilitating RWE Use in HTA: Creating a Taxonomy for Problem Solving and Data Legitimization Tuesday 28th June 2022, 12.55 – 13.55 (CEST) HTAi Annual Meeting – Utrecht, Netherlands Faculty Prof. Ron Akehurst, United Kingdom Prof. Akehurst is Executive Chair of HEOR at Lumanity and is a member of the NICE Highly Specialized Technologies Committee and Rare Diseases Advisory Group at NHS England. He is Professor Emeritus in Health Economics (University of Sheffield) and visiting Professor at Eotvos Laurent and Corvinus Universities (Budapest). He was founding Dean of ScHARR (University of Sheffield), and worked for 40 years as an academic. Ron was a founding member of the NICE Appraisal Committee and served on the NICE Topic Selection Committee, Public Health Interventions Advisory Committee and Diagnostics Advisory Committee. Dr. Oriol Solá-Morales, Spain Dr. Solá-Morales has served as Director of a regional HTA authority in Spain, is a founding member of EUnetHTA and has been advisor to three Catalan Ministers of Health. He founded HITT, an Early Market Access consultancy and has worked with major pharma as an interim MA Director, a consultant and as an advisor. He has designed and implemented medical and MA strategies for several start-ups, as well as for Top 10 pharma companies. Oriol is also an assistant professor in several Masters’ degrees, nationally and internationally. Dr. Linda Murphy, Ireland Dr. Murphy is a Senior Director of HEOR Insight at Lumanity providing HEOR support for health technologies, primarily for strategic planning for HTA submissions. Linda has worked in the MedTech industry in varying R&D and Quality Assurance roles. She has a PhD in Bioengineering and has lectured on the Bioengineering Masters course in Trinity College Dublin. She also worked as an Assessment Manager in the Health Information and Quality Authority (HIQA) in Ireland supporting HTAs to inform national policy decisions regarding medical devices, diagnostics, surgical procedures and screening programmes. Dr. Jorge Mestre-Ferrandiz, Spain Dr. Mestre-Ferrandiz is an independent economics researcher and consultant since 2017, based in Madrid, Spain. He is Profesor Asociado at University Carlos III, Madrid, and Co-Editor of the Blog Economia y Salud. Jorge spent 15 years at The Office of Health Economics with various positions, finishing as Director of Consulting. He has 20 years’ experience consulting to the pharmaceutical industry, public organizations, and related non-profit and non-governmental organizations. Jorge has a PhD in Economic Analysis from the University Autonoma of Barcelona and has published over 60 papers on health economics. To discuss the extent of this work and its value to HTA practitioners and decision makers in supporting the use of RWE in HTA. The session will focus on gathering feedback on the value of the taxonomy in its current format and how it might be improved upon. A further important strand of discussion will be on the gathering of feedback on a data governance checklist. 12.55 – 13.00 Overview of challenges of RWE use in HTA decision making – Jorge Mestre-Ferrandiz 13.00 – 13.05 Introduction to EUreccA 2025 RWE project – Ron Akehurst 13.05 – 13.20 Outputs of project: Overview of Data Governance Checklist – Oriol Solà-Morales 13.20 – 13.30 Outputs of project: Overview of Taxonomy - Ron Akehurst 13.30 – 13.40 Worked examples from Taxonomy – Linda Murphy 13.40 – 13.55 Q&A and Discussion - Jorge Mestre-Ferrandiz This satellite symposium is organized and funded by Novartis Pharma AG ©Novartis Pharma AG, 2022, CH-4002 Basel, Switzerland June 2022 108

Symposia

SYMPOSIA Symposia Monday, June 27, 2022 You Better Believe It: Methodologies to Address Concerns in Using Real-World Evidence for Measures of Treatment Effectiveness F. Hoffman-La Roche Ltd 10:45 – 12:00, Room Beatrix Theatre Moderator: Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), F. Hoffman-La Roche Ltd, Switzerland Panelists: Robert Cook, Senior Principal, Health Policy & Insights, Economist Intelligence Unit, London, United Kingdom Grace Hsu, Associate Director & Research Principal, Cytel, Canada Miguel Hernán, Professor of Biostatistics and Epidemiology, Harvard T.H. Chan School of Public Health, USA Seamus Kent, Senior Adviser in Data & Analytics, National Institute for Health and Care Excellence, United Kingdom Medicines development for rare-disease is increasingly reliant on single-arm trials which pose challenges for health technology assessment (HTA). We provide an overview of real-world evidence used in treatment effectiveness decision-making for HTA, and to understand concerns of bias regarding internal and external validity. Methodological approaches to address these concerns and results from studies applying these methods in oncology will be discussed. 110

SYMPOSIA Making Gene and Cell Therapies Reality for Patients: How HTA And Novel Payment Solutions Play a Central Role F. Hoffman-La Roche Ltd 13:15 – 14:15, Room 114 (First Floor) Moderator: Clifford Goodman, Sr Vice President, The Lewin Group, United States Panelists: Karen Facey, Evidence Based Health Policy Consultant and Visiting Senior Research Fellow, University of Edinburgh, Scotland Jessica Bean, Chair at Patient Voice Initiative, Patient Voice Initiative, Australia Samir Megatelli, Franchise Head Neuromuscular Diseases, Enabling Rare & Gene Therapy Network, Global Strategy NS&RD, F. Hoffmann-La Roche Ltd, Switzerland Bringing together diverse stakeholder perspectives, this session will explore the critical HTA role in achieving the best patient outcomes, benefiting from cell and gene therapies. This will address HTA adaptations of patient-centered priorities, challenges and solutions for these therapies, and how HTAs can ensure that the key stakeholders are engaged in ways that benefit patients, clinicians, policymakers, and innovation. 111

SYMPOSIA What does ‘Value’ mean in Cancer Policy & Practice? Interventions for Improved Patient Outcomes across Geographies Merck & Co., Inc. 13:15 – 14:15, Room 117 (First Floor) Moderator: Dr. Bettina Ryll, Founder, Melanoma Patient Network Europe Panelists: Dr. Marianna de Camargo Cancela, Section Chief, National Institute of Cancer – Brazilian Ministry of Health (Grantee, Brazil) Dr. Salvador Acevedo-Gómez, Medical Researcher, Tómatelo a Pecho A.C. (Grantee, Mexico) Dr. Patrick Jeurissen, Professor, Radboud University Medical School, London School of Economics and Political Science; Scientific Advisor, Ministry of Health, Welfare, and Sport (Policymaker) Prof. David Taylor, Professor, School of Pharmacy, University College London (Grantee, U.K.) Cancer is one of the leading causes of death worldwide and will continue to challenge diverse healthcare systems. Experts of the MSD Oncology Policy Grants Program will explore insights from their research in Brazil, Mexico, and the United Kingdom and discuss interventions they consider the most impactful to improve cancer outcomes. Together with experts from advocacy and government, they will debate the dimensions of ‘value’: How can we measure it? How can we use it for evidence-based policy and practice? 112

SYMPOSIA Tuesday, June 28, 2022 Facilitating RWE Use In HTA: Creating a Taxonomy for Problem Solving and Data Legitimization Novartis Ireland Ltd. 12:55 – 13:55, Room 114 (First Floor) Moderator: Jorge Mestre-Ferrandiz, Independent Economics Consultant, Spain Panelists: Ronald L. Akehurst, Chairman, BresMed Health Solutions, United Kingdom Oriol Solà-Morales, President Fundació HiTT & CEO at HITT, Spain Linda A. Murphy, Senior Director, Lumanity, Ireland We examined how RWE is used in HTA decision making as part of a wide collaboration to improve the usability of RWE. We recommend practical solutions to support this. We used a range of methods (literature reviews, expert elicitation, country case studies and RWE use case studies) to create a taxonomy (uses/sources) and a data governance framework. 113

SYMPOSIA Capacity-Enhancing Innovations as Enablers for Resilient Healthcare Systems Edwards Lifesciences 15:10-16:25, Room - Beatrix Theatre (Ground Floor) Moderator: Mr. Andrea Rappagliosi, Senior Vice President, Public Affairs EMEA- Canada-LatAm, Edwards Lifesciences Panelists: Dr. Sean Tunis, Center for Medical Technology Policy (CMTP) and Former President of HTAi Board of Directors Dr. Wija Oortwijn, Current President of HTAi Board of Directors and member of the HTAi Global Poliy Forum Dr. Laura Sampietro-Colom, Deputy Director of Innovation and Head of the Health Technology Assessment (HTA) Unit at the Hospital Clinic of Barcelona; Former President of HTAi Board of Directors and former Chair of HTAi Global Policy Forum and LatAm Policy Forum Dr. Seth Clancy, Senior Vice President, Global Health Economics and Reimbursement - THV, Global Public Affairs, Edwards Lifesciences Recent COVID-19 pandemic highlighted the need for more robust and agile healthcare systems. This shift, requires the adaptation of the HTA processes to maintain access to innovative technologies for all patients while securing the highest standard of care for urgent cases like COVID-19 patients. Capacity-enhancing innovations can enable access to needed care while reducing burdens on healthcare providers and hospitals. 114

Sponsors / Exhibitors

SPONSORS /EXHIBITORS Platinum Sponsors Edward Lifesciences Website: https://www.edwards.com Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube. F. Hoffman-La Roche Ltd Website: https://www.roche.com Roche focuses on finding new medicines and diagnostics and establishing data-based insights that evolve the practice of medicine and help patients live longer, better lives. Health Technology Wales Website: https://healthtechnology.wales Health Technology Wales is a national body working to improve the quality of care in Wales. It works in collaboration with partners across the health, social care and technology sectors to assess non-medicine health and care technologies for use in health and social care settings in Wales. HTW’s work informs commissioning by NHS Wales and care providers and supports decision makers to make evidence informed decisions on both technology investments and disinvestments. It is funded by Welsh Government and hosted by the Velindre University NHS Trust but is independent of both. HTW was established by ministerial recommendation in 2017 following the National Assembly for Wales’ inquiry into Access to Medical Technologies in Wales. 116

SPONSORS /EXHIBITORS HEHTA_University of Glasgow Website: https://www.gla.ac.uk/researchinstitutes/ healthwellbeing/research/hehta/ Health Economics and Health Technology Assessment HEALTH ECONOMICS and (HEHTA) is a research group at the University of Glasgow HEALTH TECHNOLOGY ASSESSMENT dedicated to research that impacts clinical practice, population health and health policies, including economic evaluation alongside trials, decision analytic modelling, evidence synthesis, population health economics, precision medicine, global HTA, medical statistics and qualitative evaluations. Radboudumc Website: https://www.radboudumc.nl/en/patient- care Radboudumc is a university medical center for patient care, research and education, located in Nijmegen, the Netherlands. We want to play a leading role in the development of innovative, sustainable and affordable healthcare. Our mission statement is: ‘to have a significant impact on healthcare’. We achieve that by providing person-oriented care, distinctive quality, efficiency and sustainable networks. Nearly 10,000 employees and 3,500 students are working on the future of healthcare and medical sciences. We participate in the Guild of European Research-Intensive Universities, comprising nineteen of Europe’s most distinguished universities in fourteen countries. The Guild is committed to the pursuit of excellence science as the foundation of public life, and the creation of new knowledge for the benefit of society, culture, and economic growth. ZonMw Website: https://www.zonmw.nl/ ZonMw stimulates health research and care innovation throughout the entire knowledge chain from fundamental research to implementation. Through various subsidy programmes we promote and fund development and practical application in the area of prevention improvement, health and care. ZonMw supports HTA with a HTA Methodology program. 117

SPONSORS /EXHIBITORS Diamond Sponsors F. Hoffman-La Roche Ltd Website: https://www.roche.com Roche is the leader in personalised healthcare. We provide breakthrough medicines and diagnostic tests using expertise in science, technology and data so that people can live better lives. Our company has a 125-year history of advancing the field of medicine and bringing novel treatments and diagnostics to patients. The patient is and will remain at the core of what we do, the reason we come to work every day. Merck & Co., Inc Website: https://www.msd.com At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. National Health Care Institute Netherlands Website: https://english. zorginstituutnederland.nl Our Mission – Taking care of good health care Every person residing or working in the Netherlands is entitled to good care services from the basic health insurance package. The National Health Care Institute is a government organization whose main task is to put together the basic health insurance package. Our goal is that everyone in the Netherlands - rich and poor, young and old, healthy and sick - can receive good care. Now and in the future. 118

SPONSORS /EXHIBITORS Novartis Pharma AG Website: https://www.novartis.com/ Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. 119

SPONSORS /EXHIBITORS Gold Sponsors Institute of Health Economics Website:https://www.ihe.ca The Institute of Health Economics is an independent, not-for-profit organisation with key competencies in health economics, health technology assessment, and knowledge transfer. Our mission is to provide relevant, timely and impactful evidence that supports informed health system policy and investment decisions, working with public and private partners. Intuitive Website: https://www.intuitive.com Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and a pioneer of robotic- assisted surgery. As part of our mission, we believe that minimally invasive care is life- enhancing care. Through ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints. Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings and develops, manufactures, and markets the da Vinci® surgical system and the Ion® robotic bronchoscopy system. Learn more at Intuitive.com. Medtronics Website: https://www,medtronic.com As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Sanofi Website: https://www.sanofi.com We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. 120

SPONSORS /EXHIBITORS Exhibitors Cochrane Website: https://training.cochrane.org/ Cochrane is delighted to announce the availability of RevMan Web, its popular, web-based systematic-review production software, to the wider community beyond Cochrane – to support evidence synthesis development. Cochrane anticipates considerable interest in use of RevMan Web from those in Guideline and Health Technology Assessment organisations. ConnectHEOR Website: https://www.connectheor.com EuroScan INAHTA Website: https://www.inahta.org The international Network of Agencies for Health Technology Assessment (INAHTA) is a network of 50 publicly funded HTA agencies that support health system decision making that affects over 1 billion people in 30 countries around the globe. INAHTA brings HTA agencies together to share knowledge and tools to strengthen their role as essential contributors to health outcomes and health system sustainability. Synergus RWE Website: https://www.synergusrwe.com/ 121